The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Open accessAbstract
The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient’s tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Self-citationGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Self-citationFehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Anderson, N. M., & Simon, M. C. (2020) · Current Biology · doi:10.1016/j.cub.2020.06.081 · Cited by 2,718
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“35,36 42 Thus, a higher TMB increases the likelihood of generating immunogenic neoantigens and a productive T-cell response 43– 48 .”
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Self-citationMacrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
Kim, S. T., Cristescu, R., Bass, A. J., Kim, K.-M., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,654
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 2×
“However, if the KRAS-mutant tumor also harboured an STK11 mutation, this was associated with reduced PD-L1 levels; or if it harboured a KEAP mutation, there was an associated reduction in T-cell infiltration and downregulation of inflammatory cytokines 70,79,82,83 .”
Self-citationThress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589 · cited 1×
“For example, in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors, ctDNA analysis at the time of resistance can identify mechanisms of resistance such as secondary EGFR mutations and MET amplification 182,184 .”
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Self-citationLoss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Jurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,470
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · cited 2×
“Indeed, JAK1/2 mutations are associated with primary resistance to checkpoint blockade in melanoma 97, 104–106 .”
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Self-citationCancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Nuclear Acids In Human Blood Plasma.
Mandel, P., & Métais, P. (1948) · PubMed · Cited by 1,196
Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Self-citationGandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0134-3 · Cited by 1,157
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Tie, J., Cohen, J. D., Lahouel, K., Lo, S. N., Wang, Y., Kosmider, S., Wong, R., Shapiro, J., Lee, M., Harris, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200075 · Cited by 1,091
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Human neoplasms elicit multiple specific immune responses in the autologous host.
Sahin, U., Türeci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., & Pfreundschuh, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11810 · Cited by 1,078
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
Self-citationScalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Adalsteinsson, V. A., Ha, G., Freeman, S. S., Choudhury, A. D., Stover, D. G., Parsons, H. A., Gydush, G., Reed, S. C., Rotem, D., Rhoades, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00965-y · Cited by 1,051
THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor Signaling
Bach, E. A., Aguet, M., & Schreiber, R. D. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.563 · Cited by 1,034
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Klein, E. A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., Chung, G., Clement, J., Gao, J., Hunkapiller, N., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.806 · Cited by 995
Self-citationCancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., & Goldhirsch, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30261-4 · Cited by 973
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Self-citationTurajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911
Self-citationMeta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893
Self-citationHenry, N. L., & Hayes, D. F. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.010 · Cited by 849
First-Line Immunotherapy for Non–Small-Cell Lung Cancer
Reck, M., Remon, J., & Hellmann, M. D. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01497 · Cited by 842
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dr�no, B., Tessier, M.-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s · Cited by 784
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Self-citationLundberg, M., Eriksson, A., Tran, B., Assarsson, E., & Fredriksson, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr424 · Cited by 744
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C.-H., Yanagitani, N., Kim, S.-W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306434 · Cited by 740
Immunogenicity of somatic mutations in human gastrointestinal cancers
Tran, E., Ahmadzadeh, M., Lu, Y.-C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., et al. (2015) · Science · doi:10.1126/science.aad1253 · Cited by 729
Integrating genomic features for non-invasive early lung cancer detection
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2140-0 · Cited by 685
Self-citationRolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.017 · Cited by 683
Self-citationLinnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 678
Extracellular microRNA: A new source of biomarkers
Etheridge, A., Lee, I., Hood, L., Galas, D., & Wang, K. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.03.004 · Cited by 659
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
Lennon, A. M., Buchanan, A. H., Kinde, I., Warren, A., Honushefsky, A., Cohain, A. T., Ledbetter, D. H., Sanfilippo, F., Sheridan, K., Rosica, D., et al. (2020) · Science · doi:10.1126/science.abb9601 · Cited by 657
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 648
Self-citationAzuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 645
Tie, J., Kinde, I., Wang, Y., Wong, H. L., Roebert, J., Christie, M., Tacey, M., Wong, R., Singh, M., Karapetis, C. S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv177 · Cited by 635
Tissue‐resident macrophages provide a pro‐tumorigenic niche to early NSCLC cells
Casanova-Acebes, M., Dalla, E., Leader, A. M., LeBerichel, J., Nikolic, J., Morales, B. M., Brown, M., Chang, C., Troncoso, L., Chen, S. T., et al. (2021) · Nature · doi:10.1038/s41586-021-03651-8 · Cited by 629
Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0237 · Cited by 623
Self-citationStrickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 620
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
D'Incecco, A., Andreozzi, M., Ludovini, V, Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.555 · Cited by 593
Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., Lanman, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0624 · Cited by 587
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
Marcus, L., Fashoyin-Aje, L. A., Donoghue, M., Yuan, M., Rodriguez, L., Gallagher, P. S., Philip, R., Ghosh, S., Theoret, M. R., Beaver, J. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0327 · Cited by 578
Soluble normal and mutated DNA sequences from single-copy genes in human blood.
Sorenson, G. D., Pribish, D. M., Valone, F. H., Memoli, V. A., Bzik, D. J., & Yao, S. (1994) · PubMed · Cited by 530
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Kotani, D., Oki, E., Nakamura, Y., Yukami, H., Mishima, S., Bando, H., Shirasu, H., Yamazaki, K., Watanabe, J., Kotaka, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02115-4 · Cited by 526
Vansteenkiste, J. F., Cho, B. C., Vanakesa, T., De Pas, T., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00099-1 · Cited by 511
Merino, D. M., McShane, L. M., Fabrizio, D., Funari, V., Chen, S.-J., White, J. R., Wenz, P., Baden, J., Barrett, J. C., Chaudhary, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000147 · Cited by 507
Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0096-5 · Cited by 487
Aggarwal, C., Thompson, J. C., Black, T. A., Katz, S. I., Fan, R., Yee, S. S., Chien, A. L., Evans, T. L., Bauml, J. M., Alley, E. W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4305 · Cited by 486
Detection and characterization of lung cancer using cell-free DNA fragmentomes
Mathios, D., Johansen, J. S., Cristiano, S., Medina, J. E., Phallen, J., Larsen, K. R., Bruhm, D. C., Niknafs, N., Ferreira, L., Adleff, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24994-w · Cited by 472
Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471
Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. E., Dahlgren, M., Schulz, R., Grabau, D., van Westen, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404913 · Cited by 453
The landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015) · Oncogene · doi:10.1038/onc.2014.406 · Cited by 450 · cited 1×
“5,6 In all these examples, a targeted therapy by HER2, EGFR, KIT, and BRAF signaling inhibitors improved the outcome of patients with metastatic cancer presenting the genomic alteration.”
Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20935-9 · Cited by 441
Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440
Odegaard, J. I., Vincent, J. J., Mortimer, S., Vowles, J. V., Ulrich, B. C., Banks, K. C., Fairclough, S. R., Zill, O. A., Sikora, M., Mokhtari, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3831 · Cited by 435
Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
Schalper, K. A., Brown, J., Carvajal-Hausdorf, D., McLaughlin, J., Velcheti, V., Syrigos, K. N., Herbst, R. S., & Rimm, D. L. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju435 · Cited by 417
O’Leary, B., Hrebien, S., Morden, J. P., Beaney, M., Fribbens, C., Huang, X., Liu, Y., Bartlett, C. H., Koehler, M., Cristofanilli, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03215-x · Cited by 414
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Wyatt, A. W., Annala, M., Aggarwal, R., Beja, K., Feng, F., Youngren, J., Foye, A., Lloyd, P., Nykter, M., Beer, T. M., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx118 · Cited by 412
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
Garcia-Murillas, I., Chopra, N., Comino-Méndez, I., Beaney, M., Tovey, H., Cutts, R. J., Swift, C., Kriplani, D., Afentakis, M., Hrebien, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1838 · Cited by 410
Mosele, F., Deluche, E., Lusque, A., Le Bescond, L., Filleron, T., Pradat, Y., Ducoulombier, A., Pistilli, B., Bachelot, T., Viret, F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02478-2 · Cited by 399
Self-citationSotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398 · cited 1×
“As example, drugs targeting specifically KRAS G12C mutations 7 and 542/545/1047 PIK3CA hotspot mutations 8 have been developed.”
Ricciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.013 · Cited by 394
Zill, O. A., Banks, K. C., Fairclough, S. R., Mortimer, S. A., Vowles, J. V., Mokhtari, R., Gandara, D. R., Mack, P. C., Odegaard, J. I., Nagy, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3837 · Cited by 391 · cited 1×
“Studies in multiple cancer types have demonstrated high concordance between ctDNA and tissue genotyping 171–175 and plasma-based genotyping has been found to recapitulate the expected tumor mutational landscape in large, multi-center cohorts 176 .”
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., et al. (2023) · Nature · doi:10.1038/s41586-023-05776-4 · Cited by 382
Self-citationThe biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Marie Nicolay, H. J., Sigalotti, L., & Maio, M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.02.001 · Cited by 375
Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00981-w · Cited by 374
Self-citationNakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1063-5 · Cited by 373
Turner, N. C., Kingston, B., Kilburn, L. S., Kernaghan, S., Wardley, A. M., Macpherson, I. R., Baird, R. D., Roylance, R., Stephens, P., Oikonomidou, O., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30444-7 · Cited by 369
MHC-I Genotype Restricts the Oncogenic Mutational Landscape
Marty, R., Kaabinejadian, S., Rossell, D., Slifker, M. J., van de Haar, J., Engin, H. B., de Prisco, N., Ideker, T., Hildebrand, W. H., Font-Burgada, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.050 · Cited by 352
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.001 · Cited by 347
Self-citationThird-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Ready, N., Farago, A. F., de Braud, F., Atmaca, A., Hellmann, M. D., Schneider, J. G., Spigel, D. R., Moreno, V., Chau, I., Hann, C. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.003 · Cited by 344
Genetic Variants Regulating Immune Cell Levels in Health and Disease
Orrù, V., Steri, M., Sole, G., Sidore, C., Virdis, F., Dei, M., Lai, S., Zoledziewska, M., Busonero, F., Mulas, A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.041 · Cited by 337
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx026 · Cited by 333
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Self-citationClinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Perez-Johnston, R., Sawan, P., Beras, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.065 · Cited by 324
Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy334 · Cited by 320
Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K., Sivakumar, I. K. A., Bruhm, D. C., Rosner, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1127 · Cited by 318
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Chowell, D., Krishna, C., Pierini, F., Makarov, V., Rizvi, N. A., Kuo, F., Morris, L. G. T., Riaz, N., Lenz, T. L., & Chan, T. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0639-4 · Cited by 306
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Passaro, A., Brahmer, J., Antonia, S., Mok, T., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01845 · Cited by 303
Self-citationOhri, C. M., Shikotra, A., Green, R. H., Waller, D. A., & Bradding, P. (2009) · European Respiratory Journal · doi:10.1183/09031936.00065708 · Cited by 296
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers
Parkhurst, M. R., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Jia, L., Ivey, G., Li, Y. F., El-Gamil, M., Lalani, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1494 · Cited by 291
Tarazona, N., Gimeno-Valiente, F., Gambardella, V., Zuñiga, S., Rentero-Garrido, P., Huerta, M., Roselló, S., Martinez-Ciarpaglini, C., Carbonell-Asins, J. A., Carrasco, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz390 · Cited by 287
Jenkins, S., Yang, J. C.-H., Ramalingam, S. S., Yu, K., Patel, S., Weston, S., Hodge, R., Cantarini, M., Jänne, P. A., Mitsudomi, T., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.003 · Cited by 269
Larson, M. H., Pan, W., Kim, H. J., Mauntz, R. E., Stuart, S. M., Pimentel, M., Zhou, Y., Knudsgaard, P., Demas, V., Aravanis, A. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22444-1 · Cited by 255
Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., Weide, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15440 · Cited by 252
Tang, Y., Fang, W., Zhang, Y., Hong, S., Kang, S., Yan, Y., Chen, N., Zhan, J., He, X., Qin, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3694 · Cited by 243
Willis, J., Lefterova, M. I., Artyomenko, A., Kasi, P. M., Nakamura, Y., Mody, K., Catenacci, D. V. T., Fakih, M., Barbacioru, C., Zhao, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1324 · Cited by 239
Knuth, A., Danowski, B., Oettgen, H. F., & Old, L. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.11.3511 · Cited by 236
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231
Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1486 · Cited by 228 · cited 1×
“For example, first generation assays can only detect MRD at the post-treatment landmark in approximately one third of early-stage NSCLC and half of colon cancer patients destined to develop recurrence 159,162,197,204– 206 .”
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
Zhang, M., Li, G., Wang, Y., Wang, Y., Zhao, S., Haihong, P., Zhao, H., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-10925-7 · Cited by 227
Higgs, B. W., Morehouse, C. A., Streicher, K., Brohawn, P. Z., Pilataxi, F., Gupta, A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3451 · Cited by 220
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-57218-9 · Cited by 215
Blomberg, O. S., Spagnuolo, L., Garner, H., Voorwerk, L., Isaeva, O. I., van Dyk, E., Bakker, N., Chalabi, M., Klaver, C., Duijst, M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.11.014 · Cited by 212
Sebastian, M., Schröder, A., Scheel, B., Hong, H. S., Muth, A., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02315-x · Cited by 209
Clark, T. A., Chung, J. H., Kennedy, M., Hughes, J. D., Chennagiri, N., Lieber, D. S., Fendler, B., Young, L., Zhao, M., Coyne, M., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.004 · Cited by 200
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Kargl, J., Zhu, X., Zhang, H., Yang, G. H. Y., Friesen, T. J., Shipley, M., Maeda, D. Y., Zebala, J. A., McKay-Fleisch, J., Meredith, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130850 · Cited by 190
Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
Wang, H., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.008 · Cited by 190
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists
Harms, P. W., Frankel, T. L., Moutafi, M., Rao, A., Rimm, D. L., Taube, J. M., Thomas, D., Chan, M. P., & Pantanowitz, L. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100197 · Cited by 177
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0220-9 · Cited by 176 · cited 1×
“TILs have demonstrated a more robust correlation with the response to checkpoint blockade compared to TMB levels in patients with PD-L1–negative disease 115 .”
Uryvaev, A., Passhak, M., Hershkovits, D., Sabo, E., & Bar-Sela, G. (2018) · Medical Oncology · doi:10.1007/s12032-018-1080-0 · Cited by 176
Shinozaki, M., O'Day, S. J., Kitago, M., Amersi, F., Kuo, C., Kim, J., Wang, H.-J., & Hoon, D. S. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2120 · Cited by 164
Soo, R. A., Lim, S. M., Syn, N. L. X., Teng, R. S. Y., Soong, R., Mok, T. S. K., & Cho, B. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.009 · Cited by 163
Damotte, D., Warren, S. E., Arrondeau, J., Boudou, P., Mansuet‐Lupo, A., Biton, J., Ouakrim, H., Alifano, M., Gervais, C., Bellesœur, A., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2100-3 · Cited by 162
Innate and adaptive immune traits are differentially affected by genetic and environmental factors
Mangino, M., Roederer, M., Beddall, M. H., Nestle, F. O., & Spector, T. D. (2017) · Nature Communications · doi:10.1038/ncomms13850 · Cited by 159
Li, B. T., Jankú, F., Jung, B. K., Hou, C., Madwani, K., Alden, R. S., Razavi, P., Reis-Filho, J. S., Shen, R., Isbell, J. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz046 · Cited by 157
Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review
Bruno, R., & Fontanini, G. (2020) · Diagnostics · doi:10.3390/diagnostics10080521 · Cited by 149
Rakaee, M., Adib, E., Ricciuti, B., Sholl, L. M., Shi, W., Alessi, J. V., Cortellini, A., Fulgenzi, C. A. M., Viola, P., Pinato, D. J., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4933 · Cited by 141
Le, X., Negrao, M. V., Reuben, A., Federico, L., Diao, L., McGrail, D. J., Nilsson, M. B., Robichaux, J. P., Guijarro, I., Patel, S. A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.010 · Cited by 135
Self-citationThompson, J. C., Davis, C. W., Deshpande, C. G., Hwang, W., Jeffries, S., Huang, A. C. C., Mitchell, T. C., Langer, C. J., & Albelda, S. Μ. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000974 · Cited by 128
Profiling cancer testis antigens in non–small-cell lung cancer
Djureinovic, D., Hallström, B. M., Horie, M., Mattsson, J. S. M., Fleur, L. L., Fagerberg, L., Brunnström, H., Lindskog, C., Madjar, K., Rahnenführer, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86837 · Cited by 127
Neutrophils in the era of immune checkpoint blockade
Faget, J., Peters, S., Quantin, X., Meylan, E., & Bonnefoy, N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002242 · Cited by 126
Self-citationPrognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Chen, X., Zhao, D., Hubbell, E. A., Kurtzman, K. N., Oxnard, G. R., Venn, O., Melton, C. A., Clarke, C. A., Shaknovich, R., Ma, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0417 · Cited by 125
Laraib, U., Sargazi, S., Rahdar, A., Khatami, M., & Pandey, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.12.052 · Cited by 121
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely
Calles, A., Riess, J. W., & Brahmer, J. R. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280795 · Cited by 118
Varkaris, A. S., Pazolli, E., Günaydin, H., Wang, Q., Pierce, L., Boezio, A. A., Bulku, A., DiPietro, L., Fridrich, C., Frost, A. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0944 · Cited by 118
Self-citationCell types of origin of the cell-free transcriptome
Vorperian, S. K., Moufarrej, M. N., Tabula Sapiens Consortium, Overall Project Direction and Coordination, Jones, R. C., Karkanias, J., Krasnow, M., Pisco, A. O., Quake, S. R., Salzman, J., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01188-9 · Cited by 116
Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
Burgener, J., Zou, J., Zhao, Z., Zheng, Y., Shen, S. Y., Huang, S. H., Keshavarzi, S., Xu, W., Liu, F., Liu, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0110 · Cited by 114
McEvoy, A. C., Warburton, L., Al‐Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., Khattak, M. A., Meniawy, T. M., Millward, M., Ziman, M. R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4637-6 · Cited by 108
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Althammer, S., Tan, T. H., Spitzmüller, A., Rognoni, L., Wiestler, T., Herz, T., Widmaier, M., Rebelatto, M. C., Kaplon, H., Damotte, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0589-x · Cited by 104
Jin, J., Yang, L., Liu, D., & Li, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035031 · Cited by 103
Expósito, F., Redrado, M., Houry, M., Hastings, K., Molero-Abraham, M., Lozano, T., Solórzano, J. L., Sanz‐Ortega, J., Adradas, V., Amat, R., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3023 · Cited by 102
Koh, J., Hur, J. Y., Lee, K. Y., Kim, M. S., Heo, J. Y., Ku, B. M., Sun, J., Lee, S., Ahn, J. S., Park, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76130-1 · Cited by 100
Next generation pan-cancer blood proteome profiling using proximity extension assay
Álvez, M. B., Edfors, F., von Feilitzen, K., Zwahlen, M., Mardinoğlu, A., Edqvist, P.-H. D., Sjöblom, T., Lundin, E., Rameika, N., Enblad, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39765-y · Cited by 94
Yeong, J. P.-S., Suteja, L., Simoni, Y., Lau, K. W., Tan, A. C., Li, H. H., Lim, S., Loh, J. H., Wee, F. Y. T., Nerurkar, S. N., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.016 · Cited by 86
Ren, A. H., Diamandis, E. P., & Kulasingam, V. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100155 · Cited by 86
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1860586 · Cited by 79
Self-citationYang, T., Hao, L., Yang, X., Luo, C., Wang, G., Cai, C. L., Qi, S., & Li, Z. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049123 · Cited by 77
Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study
Hashemi, S. M. S., Fransen, M. F., Niemeijer, A.-L. N., Taleb, N., Houda, I., Veltman, J. D., Becker‐Commissaris, A., Daniels, J. M. A., Crombag, L. M. M. J., Radonic, T., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.01.013 · Cited by 76
Shirasawa, M., Yoshida, T., Shimoda, Y., Takayanagi, D., Shiraishi, K., Kubo, T., Mitani, S., Matsumoto, Y., Masuda, K., Shinno, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.027 · Cited by 75
Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics, and Therapeutics
Mehan, M. R., Ostroff, R. M., Wilcox, S. K., Steele, F. R., Schneider, D. J., Jarvis, T. C., Baird, G. S., Gold, L., & Janjić, N. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4118-2_20 · Cited by 69
Multiplex Immunofluorescence Assays
Francisco‐Cruz, A., Parra, E. R., Tetzlaff, M. T., & Wistuba, I. I. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_22 · Cited by 69
Self-citationGraumann, J., Finkernagel, F., Reinartz, S., Stief, T. W., Brödje, D., Renz, H., Jansen, J. M., Wagner, U. A. G., Worzfeld, T., von Strandmann, E. P., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01150 · Cited by 67
Germline Features Associated with Immune Infiltration in Solid Tumors
Shahamatdar, S., He, M. X., Reyna, M. A., Gusev, A., AlDubayan, S. H., Allen, E. M. V., & Ramachandran, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.039 · Cited by 67
Pagadala, M. S., Sears, T. J., Wu, V. H., Pérez‐Guijarro, E., Kim, H., Castro, A., Talwar, J. V., González-Colín, C., Cao, S., Schmiedel, B. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38271-5 · Cited by 66
In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens
Parvizpour, S., Razmara, J., Pourseif, M. M., & Omidi, Y. (2018) · Bioimpacts · doi:10.15171/bi.2019.06 · Cited by 62
Chen, B., Li, H., Liu, C., Xiang, X., Wang, S., Wu, A., Shen, Y., & Li, G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242173 · Cited by 62
A review of HER2 overexpression and somatic mutations in cancers
Galogre, M. I., Rodin, D., Pyatnitskiy, M. A., Mackelprang, M., & Koman, I. E. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103997 · Cited by 60
The innate immune architecture of lung tumors and its implication in disease progression
Milette, S., Fiset, P., Walsh, L. A., Spicer, J. D., & Quail, D. F. (2019) · The Journal of Pathology · doi:10.1002/path.5241 · Cited by 58
Socinski, M. A., Velcheti, V., Mekhail, T. M., Chae, Y. K., Leal, T. A. B., Dowell, J. E., Tsai, M. L., Dakhil, C. S. R., Stella, P. J., Shen, V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.081 · Cited by 56
MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
Mao, Y., Fan, W., Hu, H., Zhang, L., Michel, J., Wu, Y., Wang, J., Jia, L., Tang, X., Xu, L., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0793-7 · Cited by 54
Niemeijer, A.-L. N., Sahba, S., Smit, E. F., Lissenberg-Witte, B. I., Langen, A. J. D., & Thunnissen, E. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0888-5 · Cited by 54
Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer
Kruglyak, K. M., Lin, E., & Ong, F. S.-C. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_7 · Cited by 53
The role of MYH and microsatellite instability in the development of sporadic colorectal cancer
Colebatch, A. J., Hitchins, M. P., Williams, R., Meagher, A. P., Hawkins, N. J., & Ward, R. L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603421 · Cited by 52
Alves, A., Dias, M., Campainha, S., & Barroso, A. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3525 · Cited by 47
Streicher, K. L., Higgs, B. W., Wu, S., Coffman, K. T., Damera, G., Durham, N., Greenlees, L. M., Lazdun, Y., Li, C., Cooper, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11505 · Cited by 45
Hummelink, K., van der Noort, V., Muller, M., Schouten, R. D., Lalezari, F., Peters, D. D. G. C., Theelen, W. S. M. E., Koelzer, V. H., Mertz, K. D., Zippelius, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0992 · Cited by 45
Metzenmacher, M., Váraljai, R., Hegedűs, B., Cima, I., Förster, J., Schramm, A. R., Scheffler, B., Horn, P., Klein, C. A., Szarvas, T., et al. (2020) · Cancers · doi:10.3390/cancers12020353 · Cited by 43
Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases
He, Y., Lu, H., & Zhang, L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.01.001 · Cited by 40
Jang, H.-J., Lee, H., Ramos, D., Park, I. K., Kang, C. H., Burt, B. M., & Kim, Y. T. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.10.123 · Cited by 40
Dowlatshahi, S., & Abdekhodaie, M. J. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.01.018 · Cited by 37
Cited by
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects
Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., & Uddin, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117535 · Cited by 119
The impact of AI on modern oncology from early detection to personalized cancer treatment
Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., & Wang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01276-6 · Cited by 24
Metadata
- Authors
- Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 187
- Issue
- 7
- Pages
- 1617-1635
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4393251590
- Cited by
- 672
- References
- 215
- FWCI
- 102.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.